Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.
Elaine Sanders‐bush, M Breeding
Psychopharmacology 1991 DOI: 10.1007/bf02244428 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | In vitro pharmacological study Peer reviewed |
|---|---|
| Population | Epithelial cells isolated from rat choroid plexus |
| Interventions | 2 5-Dimethoxy-4-bromoamphetamine (DOB) 5-Dimethoxy-4-methylamphetamine (DOM) 5-Dimethoxy-4-iodoamphetamine (DOI) 3 4-Methylenedioxyamphetamine (MDA) 5-methoxy-N N-dimethyltryptamine 5-methoxytryptamine |
| Measures | phosphoinositide hydrolysis |
| Key points | The rank order of hallucinogen potency at activating 5HT1C receptors corresponded to the rank order of effective behavioral doses in rats and humans, and the indolealkylamines 5-methoxy-N,N-dimethyltryptamine and 5-methoxytryptamine also activated these receptors. The authors suggest that investigations of hallucinogen mechanisms should consider 5HT1C receptors in addition to 5HT2 receptors. |
Abstract
Behavioral, electrophysiological and biochemical evidence suggest that the 5HT2 receptor plays a role in the action of hallucinogenic agents. Considering the structural and functional similarities between the 5HT2 and 5HT1C receptors, we hypothesized that the 5HT1C receptor may also be an important site of action of hallucinogens. The present manuscript evaluates this hypothesis by examining the properties of hallucinogens in the phenalkylamine and indolealkylamine classes at 5HT1C receptors. Epithelial cells isolated from the rat choroid plexus have a high density of 5HT1C receptors linked to phosphoinositide hydrolysis. Comparison of the actions of drugs in cultured cells and whole choroid plexus confirmed that the cell culture system can serve as an in vitro model of 5HT1C receptor activation. 2,5-Dimethoxy-4-bromoamphetamine (DOB), 2,5-dimethoxy-4-methylamphetamine (DOM), 2,5-dimethoxy-4-iodoamphetamine (DOI) and 3,4-methylenedioxyamphetamine (MDA) were evaluated. The rank order of potency to activate 5HT1C receptors [(-)DOB greater than (+/-) DOI greater than (+)DOB greater than (-)DOM much greater than (-)MDA greater than (+) MDA] was consistent with the rank order of effective behavioral doses in rats and humans. The indolealkylamine hallucinogen, 5-methoxy-N,N-dimethyltryptamine was also a 5HT1C receptor agonist, as is the primary amine, 5-methoxytryptamine. These data, combined with previous studies showing that (+)LSD potently activates 5HT1C receptors, suggest that future investigations of the mechanism of action of hallucinogens should consider the role of 5HT1C receptors in addition to the more commonly investigated 5HT2 receptors.
Citations in the library
Cited by 22
- 5-HT2AReceptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex Journal of Neuroscience April 15, 1997
- Agonist Properties of N,N-Dimethyltryptamine at Serotonin 5-HT2A and 5-HT2C Receptors Pharmacology, Biochemistry, and Behavior November 1, 1998
- Adverse consequences of lysergic acid diethylamide Addiction October 1, 1993
- d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology International Journal of Molecular Sciences November 23, 2016
- The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen Psychopharmacology February 19, 2010
and 17 more in the library
Cites 7
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences December 17, 1984
- 125I-lysergic acid diethylamide binds to a novel serotonergic site on rat choroid plexus epithelial cells Journal of Neuroscience December 1, 1985
- Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. Journal of Pharmacology and Experimental Therapeutics September 1, 1988
- (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. Journal of Pharmacology and Experimental Therapeutics September 1, 1991
- Studies of dioxole ring substituted 3,4-methylenedioxyamphetamine (MDA) analogues. Pharmacology, Biochemistry, and Behavior November 1989
and 2 more in the library